Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for circulating tumour cells (CTCs) in venous whole blood — Part 3: Preparations for analytical CTC staining
Introduction: Solid tumours release cells and bioanalytes into blood and other body fluids. This has opened the option of utilizing such body fluids (liquid biopsies) for a minimally-invasive procedure for tumour detection, diagnosis and characterization. Liquid biopsies can enable earlier detection and diagnosis of cancers and advance personalized patient treatment.[19,20] These applications have become one of the fastest growing segments of the entire diagnostic market. Circulating tumour cells (CTCs) in venous whole blood can reflect the disease complexity that evolves during tumour progression, with distinct genetic, epigenetic and expression features.[21] Besides the prognostic role of CTC identification and enumeration in cancer progression, CTC identification and analysis can improve disease outcome prediction, therapeutic guidance and post-treatment monitoring of the patient.[19] CTCs are now considered as a surrogate of tumour tissue in cancer early development, progression and metastatic phase.[22] Molecular characterization of CTCs can provide a strategy for monitoring cancer during systemic therapies,[23] identifying mechanisms of disease progression, identifying novel targets for treatment[24] and selecting targeted therapies[19]. CTCs are fragile and tend to degrade within a few hours when collected in conventional blood collection tubes, e.g. EDTA containing tubes, without dedicated CTC stabilizers. CTCs are extremely rare, especially in early disease, e.g. less than 10 cell
Scope: This document specifies requirements and gives recommendations on the handling, storage, CTC enrichment, preparation for CTC staining, and documentation of venous whole blood specimens intended for staining of CTCs during the pre-examination phase before an examination is performed. This document is applicable to molecular in vitro diagnostic examinations including laboratory developed tests performed by medical laboratories. It is also intended to be used by laboratory customers, in vitro diagnostics developers, and manufacturers, biobanks, institutions, and commercial organizations performing biomedical research, and regulatory authorities. This document does not cover pre-analytical workflow requirements for viable CTC cryopreservation and culturing. Different dedicated measures are taken for stabilizing CTCs genomic DNA and RNA that are not described in this document; they are covered in ISO 7552-1 and ISO 7552-2. NOTE 1 The requirements given in this document can also be applied to other circulating rare cells (e.g. foetal cells). NOTE 2 International, national or regional regulations or requirements can also apply to specific topics covered in this document.